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Commentary 
Stroke prevention is central to the management of atrial fibrillation (AF). The approach is to initially 
identify patients at a low risk for stroke (CHA2DS2-VASc score of 0 [men] or 1 [women]), who do 
not need any antithrombotic therapy. Subsequent to this step, patients with ≥ additional stroke risk 
factors (thus, CHA2DS2-VASc score of ≥2, as well as men with a score of 1) can be offered effective 
stroke prevention. 
Effective stroke prevention essentially means oral anticoagulation (OAC), whether given as a well-
controlled, adjusted-dose vitamin K antagonist (VKA; eg, warfarin), or one of the non-VKA oral 
anticoagulants (NOACs; previously referred to as new, or novel, OACs1). If VKAs are used, the 
challenge is to maintain patients within an international normalized ratio (INR) of 2.0 to 3.0. 
Guidelines recommend good-quality anticoagulation control, as reflected by an average individual 
time in therapeutic range (TTR) of ≥70%.2,3 The TTR correlates with the efficacy and safety of 
VKAs whereby a high TTR is associated with low risks for thromboembolism and bleeding, but a 
low TTR (ie, <60%) is associated with a high risk for thromboembolism or hemorrhage.3,4 
For newly diagnosed anticoagulation-naïve patients with AF, use of the SAMe-TT2R2score can help 
identify those patients (SAMe-TT2R2 score of 0–2) who are likely to do well with a VKA (with TTR 
≥70%). On the other hand, patients with a SAMe-TT2R2score >2 are less likely to do well with a 
VKA and require more intense review and INR monitoring; therefore, they may be better off with an 
NOAC.5 We do not practice a "warfarin stress test" whereby patients are initiated with a VKA for 3 
to 6 months, and only if the TTR is suboptimal would they be permitted to switch to an NOAC. Such 
an approach leads to the initial period whereby patients in the inception cohort would have 
suboptimal TTRs and would lead to a substantial risk for fatal and devastating strokes.6 
In an established patient who is already receiving anticoagulation with a VKA, clinical follow-up 
includes a review of the INRs recorded in the anticoagulation record booklet. If the TTR is 
suboptimal (ie, <60% despite efforts to improve anticoagulation control by our clinic), the patient 
would be considered for switching from a VKA to an NOAC. The VKA is stopped, the INR is 
allowed to decrease to approximately 2.0, and the NOAC is started.7,8 Because all of the NOACs 
have a fast onset of action, no bridging is necessary. 
With the availability of a number of NOACs, prescribers are now spoiled regarding choice, and we 
can fit the drug to a particular patient profile (and vice versa). For example, in a patient with a high 
risk for bleeding (HAS-BLED score ≥3), the NOACs that have a safer bleeding profile (eg, 
dabigatran 110 mg twice daily or apixaban) can be used. When renal function is impaired (eg, 
creatinine clearance ≈30 mL/L), it would be prudent to use an NOAC that is not so dependent on 
renal excretion, such as apixaban and rivaroxaban. Dabigatran should be avoided, given the high 
renal excretion of this drug. For maximal potency in reducing ischemic stroke (eg, in a patient with 
recurrent strokes despite reasonable TTR), dabigatran 150 mg twice daily can be considered. 
My patients starting with any OAC are given a counseling or education session, focused on 
compliance and precautions about use of anticoagulants. Part of the counseling process is drug-
specific (eg, advice not to take dabigatran on an empty stomach to avoid any dyspepsia). Also, 
rivaroxaban needs to be taken with food. Follow-up at intervals requires assessment of any changes 
in the clinical situation (eg, bleeding problems) and monitoring of renal function. 
 
 Abbreviations 
SAMe-TT2R2 Sex female; Age <60 years; Medical history (>2 comorbidities); Treatment (interacting 
medications; eg, amiodarone); Tobacco use (doubled); Race (doubled) 
CHADS2 Congestive heart failure; Hypertension; Age ≥75 years; Diabetes; previous Stroke 
CHA2DS2-
VASc 
Congestive heart failure, Hypertension, Age ≥75 years, Diabetes, previous Stroke, Vascular 
disease, Age 65-74 years, Sex category (female) 
HAS-BLED Hypertension; Abnormal renal/liver function; Stroke; Bleeding history or predisposition; 
Labile international normalized ratio; Elderly (>65 years);Drugs/alcohol concomitantly 
VKA Vitamin K antagonist 
TTR Time in therapeutic range 
OAC Oral anticoagulation 
NOAC Non-VKA oral anticoagulant 
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